Biomoda Inc. Readies Products to Assist Medicare and Private Insurer Reimbursement Outsourcing to Speed Entry into Commercial Cancer Detection and Treatment.ALBUQUERQUE, N.M. -- Biomoda Inc. has contracted with JR Associates (www.1jra.com) to help advance Biomoda's patented products, primarily involved with early detection and targeted treatment of specific cancers, potential for securing positive coverage, coding, and payment by Medicare and commercial insurers. Ultimately, these activities will assure patient access to Biomoda's products and systems. JR Associates, Reseda, Calif., is prominent in the field of reimbursement Reimbursement Payment made to someone for out-of-pocket expenses has incurred. strategies and has provided services to many major makers of medical products and systems. Reimbursement and coding are critical issues to medical reference laboratories, Biomoda's anticipated primary market. Biomoda Inc., a development stage in-vitro diagnostics organization, is focused on research, development and commercialization of cancer diagnostics. The company, exclusive worldwide licensee licensee n. a person given a license by government or under private agreement. (See: license, licensor) LICENSEE. One to whom a license has been given. 1 M. Q. & S. 699 n. from the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). of several patents developed for noninvasive non·in·va·sive adj. 1. Not penetrating the body, as by incision. Used especially of a diagnostic procedure. 2. Not invading healthy tissue. early detection and treatment of lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. , is in the process of registering additional patents in this area. The company's proprietary technologies provide minimally invasive and minimal impact approaches as cancer diagnostic products. Operating from its laboratory situated at Kirtland Air Force Base Kirtland Air Force Base is located in the southeast quadrant of Albuquerque, New Mexico, adjacent to the Albuquerque International Sunport. The base is the third largest installation in Air Force Materiel Command, covering 51,558 acres (209 km²) and employing over 23,000 people, (Albuquerque, N.M.), the company is in the process of expanding and expediting its product development and commercialization with a number of strategic alliances that will be announced over the next 60 days. This news release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve a high degree of risk and uncertainty. Such statements include, but are not limited to, statements containing the words "believes," "anticipates," "expects," "estimates," and words of similar import. The company's actual results could differ materially from any forward-looking statements, which reflect management's opinions only as of the date of this report, as a result of risks and uncertainties that exist in our operation, development efforts and business environment. The company undertakes no obligation to revise or publicly release the results of any revisions to these forward-looking statements. You should carefully review the risk factors in other documents that the company files from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. . For additional information, visit the Biomoda Web site at www.biomoda.com or call us at 505-821-0875. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion